Internal Medicine Alert – September 30, 2025

The Walk ’n Watch Trial: Stroke Recovery Through High-Intensity Walking

An intensive real-life walking protocol, started as soon as possible after acute stroke, resulted in improved overall walking endurance, mobility, balance, and quality of life

Community-Acquired Pneumonia Guidelines: Updates and Disputes

An update of elements of community-acquired pneumonia guidelines has been published. Of note is that these were not endorsed by the Infectious Diseases Society of America because of disagreement over recommendations for empiric antibiotic administration to some patient subsets with positive tests for respiratory viral infection.

Statins for Abdominal Aortic Aneurysms

An analysis of two large, abdominal aortic aneurysm (AAA) screening populations from Denmark has shown that high-dose statin therapy reduces the rate of AAA growth, the need for repair, and adverse outcomes, such as rupture and death.

Beta-Blocker Interruption Post-MI

An analysis of the secondary outcomes in the French multicentered study of beta-blocker withdrawal in patients with uncomplicated myocardial infarction after one year led to increases in heart rate and blood pressure with potentially deleterious outcomes, especially in patients with a history of hypertension.

The Health and Economic Burden of Long COVID in the United States

Researchers using a computational simulation model found that the current health and economic burden of long COVID already exceeds the cost of several chronic diseases and will continue to grow as COVID-19 cases increase.

Brensocatib Tablets (Brinsupri)

The U.S. Food and Drug Administration has approved brensocatib, the first dipeptidyl peptidase-1 inhibitor and the first drug approved for non-cystic fibrosis bronchiectasis.